Nrh A News Today

The expanded approval makes enzalutamide the first and only approved androgen receptor signaling inhibitor in the nonmetastatic castration-sensitive prostate cancer setting.

In a subset of patients with high-risk prostate cancer, the combination of abiraterone acetate plus prednisone (AAP) and apalutamide may improve outcomes when added to salvage radiation therapy.

Although the disease afflicts at least 1 out of every 10 women, endometriosis remains a conundrum for patients and their physicians.

It appears that bone health deserves attention when adolescents are placed on gender-affirming hormone therapy.

In premenopausal women with early breast cancer, use of a gonadotropin-releasing hormone agonist during chemotherapy did not increase the risk of cancer recurrence for up to 12 years, according to the PROMISE-GIM6 trial.